{"id":"W3088466047","doi":"10.1016/j.annonc.2020.08.2070","title":"799TiP PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Hazard ratio; Oncology; Placebo; Tolerability; Cisplatin; Adjuvant therapy; Urology; Chemotherapy; Randomized controlled trial; Adverse effect; Pathology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006347882,0.0002579737,0.001149487,0.0001768657,0.00004937479,0.00001715185,0.0003025544,0.0002364486,0.0000819633],"category_scores_gemma":[0.0006263027,0.0002002289,0.0002454591,0.0002388949,0.000286873,0.00002070316,0.0001068715,0.0002328231,0.000003987228],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001647535,"about_ca_system_score_gemma":0.001051712,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001932608,"about_ca_topic_score_gemma":0.0002266333,"domain_scores_codex":[0.9974141,0.0005504016,0.0008730869,0.0004363874,0.0003384742,0.000387613],"domain_scores_gemma":[0.9982464,0.0002554778,0.0004969211,0.0002969444,0.0005428504,0.000161397],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8789885,0.00124448,0.001281062,0.00003692577,0.0002944993,0.000007276763,0.0006189526,0.0001213196,0.1160035,0.00006670225,0.0002031962,0.001133618],"study_design_scores_gemma":[0.6843846,0.0311821,0.00004825857,0.00002011713,0.00002233533,8.169673e-7,0.0000532344,0.00004668162,0.2837159,0.00001463692,0.0003787966,0.0001324628],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919001,0.0001752358,0.00007689411,0.0008528686,0.00007634214,0.005898,0.00005609091,0.000006430698,0.000958067],"genre_scores_gemma":[0.9982904,0.0001215292,0.0001072572,0.0003201514,0.0001980704,0.0007307174,0.000155053,0.00003191937,0.00004488292],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1946039,"threshold_uncertainty_score":0.8165097,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06522590316561952,"score_gpt":0.3628403563382298,"score_spread":0.2976144531726103,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}